Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
AVITA Medical reports developments in therapeutic acute wound care, led by the RECELL platform for Spray-On Skin used in burn and trauma wounds. Company news commonly covers FDA-cleared wound-care indications, RECELL GO automation, international regulatory clearances, and the U.S. commercial portfolio that includes Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix.
Updates also include clinical data presentations, BARDA emergency-preparedness agreements, quarterly financial results, investor-conference participation, and board or executive governance changes. The recurring news themes connect AVITA Medical's product platform with acute burn care, trauma wound treatment, commercialization, reimbursement, and capital resources.
AVITA Medical (RCEL) will participate in two investor events in New York in September 2026: Lake Street Capital Markets’ 10th Annual Best Ideas Growth Conference on September 10 and Morgan Stanley’s 24th Annual Global Healthcare Conference on September 16.
President and CEO Cary Vance and CFO David O’Toole will host investor meetings at both conferences and join a fireside chat at the Morgan Stanley event at 1:05 p.m. ET. A live audio webcast and 90-day replay of this fireside chat will be accessible in the Investor Relations section of AVITA Medical’s website.
AVITA Medical (NASDAQ: RCEL) reported positive results from its multicenter, randomized controlled PermeaDerm-I study, showing PermeaDerm, a biosynthetic wound matrix, achieved the primary endpoint of a 70% economic advantage over cadaveric allograft based on mean product cost per percent total body surface area (%TBSA) treated (p<0.001).
According to the company, mean treatment cost was $148.70 per 1% TBSA with PermeaDerm versus $497.10 with allograft, a savings of about $348 per %TBSA. PermeaDerm reduced preparation time by 95.7% by eliminating tissue tracking, thawing, and meshing, while maintaining comparable operating room application time.
Clinical outcomes were comparable: about 94% of PermeaDerm patients achieved at least 95% graft take at one week, and all patients in both arms reached ≥95% wound healing by eight weeks, with no adverse events attributed to PermeaDerm. The study enrolled 40 patients across 11 U.S. burn centers. AVITA Medical will host a Key Opinion Leader webinar to review the data on August 18, 2026, at 4:30 p.m. ET.
AVITA Medical (NASDAQ: RCEL, ASX: AVH) will host an investor webinar briefing on August 12, 2026, at 4:00 p.m. Pacific Time (August 13, 2026, 9:00 a.m. AEST). President and CEO Cary Vance and CFO David O’Toole will present financial and business highlights from the recent Q2 2026 earnings webcast, followed by a Q&A session. Investors can register via Zoom, and a replay will be available on the AVITA Medical investor relations website.
AVITA Medical (NASDAQ: RCEL, ASX: AVH) will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, held August 11–13, 2026. President and CEO Cary Vance is scheduled to speak on Wednesday, August 12, 2026, at 8:00 a.m. Eastern Time.
A live webcast and replay of the presentation will be accessible via the Investor Relations Events & Presentations section of AVITA Medical’s website. Investors attending the conference can request one-on-one meetings with AVITA Medical through their Canaccord Genuity sales representative.
AVITA Medical (NASDAQ: RCEL) reported Q2 2026 revenue of $21.7 million, up 18% year over year and 13% sequentially, with a record gross margin of 81.9% and operating expenses reduced 6% to $24.6 million. Net loss improved to $7.7 million ($0.25 per share).
Growth was led by RECELL (Q2 revenue $18.5 million), supported by Cohealyx ($1.7 million), PermeaDerm ($0.6 million), and international sales ($0.9 million). According to AVITA Medical, net cash use fell to approximately $3.2 million, with quarter-end liquidity of $11.1 million.
The company raised its 2026 revenue guidance to $86–$89 million (20–24% growth over 2025) and now expects cash flow breakeven in Q4 2026. AVITA Medical also highlighted proposed 2027 CMS Medicare payment updates for procedures using RECELL that would introduce national physician payment and higher facility rates if finalized.
AVITA Medical (NASDAQ: RCEL, ASX: AVH) announced it will release its second quarter 2026 financial results after the close of U.S. financial markets on Thursday, August 6, 2026.
The company will host a conference call and webcast at 1:30 p.m. Pacific Time the same day (6:30 a.m. AEST on Friday, August 7, 2026) to review results and recent business highlights. Investors can access the webcast and register for dial-in details via provided online links, and a replay will be available on the investor relations Events page.
AVITA Medical (NASDAQ: RCEL) reported first U.K. clinical experience with RECELL GO in 17 burn and reconstructive patients at the 2026 British Burn Association meeting.
According to AVITA Medical, all patients had successful treatment and discharge, with noted workflow benefits, and RECELL GO is CE-marked in Europe/U.K. and authorized in Australia and New Zealand. A separate review of 99 studies in 8,000+ patients found RECELL to be a safe, effective, evidence-based wound management approach.
AVITA Medical (NASDAQ:RCEL) will host an investor webinar on May 20, 2026 at 4:00 p.m. PT (May 21, 2026 at 9:00 a.m. AEST), featuring President and CEO Cary Vance and CFO David O’Toole. The event will review recent Q1 2026 earnings results and include a Q&A session.
The company will also hold an in-person armchair investor discussion in Melbourne on May 21, 2026 at 4:00 p.m. AEST, covering its acute wound care platform, portfolio, commercial progress, and 2026 execution priorities. Replays of both events will be available on AVITA Medical’s investor relations website.
AVITA Medical (NASDAQ: RCEL) reported Q1 2026 revenue of approximately $19.3 million, up 4% year-over-year and ~10% sequentially, with gross margin of 81.7% and operating expenses down 11% to $24.5 million.
Net loss improved to $10.6 million ($0.35/share). The company reaffirmed 2026 revenue guidance of $80–$85 million, entered a 10-year BARDA agreement worth up to $25.5 million, announced positive interim Cohealyx data, and received RECELL GO clearance in Australia and New Zealand. Leadership changes include Cary Vance as CEO and Jan Stern Reed as Board Chair.
AVITA Medical (NASDAQ: RCEL) appointed Cary Vance as President and Chief Executive Officer, effective April 30, 2026, after serving as Interim CEO since October 2025. The Board also named Jan Stern Reed as Chair, effective immediately. Mr. Vance will remain on the Board as an executive member.
The Board described a thorough search and credited Vance with stabilizing the business, sharpening strategic focus, and rebuilding stakeholder confidence during his interim tenure. Leadership will prioritize scaling clinical adoption of AVITA’s acute wound care platform and translating momentum into consistent performance.